Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Myelofibrosis Resource Center

Featured

News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
From Oncology
Eytan M Stein, MD
Q&As
Preventing Transformation and Adverse Events Among Patients With Myelofibrosis
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert...
03/07/2024
Oncology
From Oncology
News
Patients With Myelofibrosis Are at Higher Risk for Poor Cardiovascular Outcomes After Heart Failure Hospitalization
03/05/2024

Grace Taylor

Grace Taylor
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues...
03/05/2024
Journal of Clinical Pathways
News
Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib
02/27/2024

Jordan Kadish

Jordan Kadish
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically...
02/27/2024
Oncology
From Oncology
News
Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis
02/23/2024

Jordan Kadish

Jordan Kadish
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to...
02/23/2024
Oncology
From Oncology
Aaron Gerds, MD
Videos
Mitigating Potential Treatment Risks Among Patients With Myelofibrosis
02/02/2024

Featuring Aaron Gerds, MD

Featuring Aaron Gerds, MD
Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.
Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.
Aaron Gerds, MD, examines...
02/02/2024
Oncology
From Oncology
News
Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis
01/22/2024

Jordan Kadish

Jordan Kadish
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment...
01/22/2024
Oncology
From Oncology

Newsfeed

News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
News
Patients With Myelofibrosis Are at Higher Risk for Poor Cardiovascular Outcomes After Heart Failure Hospitalization
03/05/2024

Grace Taylor

Grace Taylor
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues...
03/05/2024
Journal of Clinical Pathways
News
Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib
02/27/2024

Jordan Kadish

Jordan Kadish
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically...
02/27/2024
Oncology
News
Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis
02/23/2024

Jordan Kadish

Jordan Kadish
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to...
02/23/2024
Oncology
News
Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis
01/22/2024

Jordan Kadish

Jordan Kadish
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment...
01/22/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
News
FDA Approves Momelotinib for Patients With Anemia and Myelofibrosis
10/27/2023

Emry Lloyd

Emry Lloyd
On September 15, 2023, the FDA approved momelotinib for the treatment of adult patients with myelofibrosis and anemia.
On September 15, 2023, the FDA approved momelotinib for the treatment of adult patients with myelofibrosis and anemia.
On September 15, 2023, the FDA...
10/27/2023
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Conference Coverage

Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...
At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the 2023 ASH Annual Meeting,...
01/03/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
Conference Coverage
Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
12/07/2023

Edited by Grace Taylor

Edited by Grace Taylor
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS,...
12/07/2023
Journal of Clinical Pathways
Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Videos
Novel Advances in the Treatment of Patients With Myelofibrosis
11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023

Marta Rybczynski

Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve
01/31/2023

Yvette C Terrie

Yvette C Terrie
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis
01/31/2023

Yvette C Terrie

Yvette C Terrie
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023

Yvette C Terrie

Yvette C Terrie
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Conference Coverage
Cybersecurity, Drug Shortages, and PBMs: Legislative Updates Impacting Oncology
04/12/2024

Grace Taylor

Grace Taylor
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry...
04/12/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement